In the global competitive landscape of structural heart disease interventional devices, valvular heart disease represents a core sub-track, which is further divided into three major technical areas: aortic valve, mitral valve, and tricuspid valve. These areas differ significantly in disease characteristics, technical barriers, and the layout strategies of domestic and foreign manufacturers. The aortic valve market is highly developed, with overseas leaders such as Edwards Lifesciences, Medtronic, and Abbott having a strong first-mover advantage. Domestic companies like Venus Medtech, MicroPort, and Peijia Medical have achieved technical parity and large-scale import substitution. The mitral valve market is in a rapid growth phase; foreign TEER devices have long dominated the market, while domestic repair products developed by Djn Medical and HanYu Medical have achieved commercial success. The tricuspid valve segment remains a blue ocean. Foreign repair and replacement devices lack sufficient clinical data, whereas HuiHe Medical’s K-Clip, the first approved tricuspid annuloplasty system in China, offers exclusive local technical advantages.
Overseas companies led by Edwards Lifesciences, Abbott, and Medtronic, along with domestic innovators such as Venus Medtech, Djn Medical, and HuiHe Medical, have established distinct competitive advantages through proprietary track-specific technologies, comprehensive product lines, clinical evidence systems, and localized services, collectively driving continuous progress in the global valvular intervention industry.
Looking ahead, competition in the aortic and mitral valve markets will become more normalized, while the tricuspid valve segment will become the core growth area of the industry. Original domestic technologies represented by HuiHe Medical will create new growth opportunities. The mature operational models of multinational enterprises and the localized innovation approaches of Chinese manufacturers serve as valuable industry benchmarks. By learning from both models, we can promote balanced development in the global structural heart valvular device industry and support its sustainable, long-term expansion.
Within the global competitive environment of structural heart disease interventional devices, valvular heart disease forms a core sub-track, which is further divided into three major technical areas: aortic valve, mitral valve, and tricuspid valve. These areas vary significantly in terms of disease characteristics, technical challenges, and the strategic arrangements of domestic and foreign manufacturers. The aortic valve market is highly developed, with overseas leaders such as Edwards Lifesciences, Medtronic, and Abbott enjoying a strong first-mover advantage. Domestic companies like Venus Medtech, MicroPort, and Peijia Medical have achieved technical parity and large-scale import substitution. The mitral valve market is experiencing rapid growth; foreign TEER devices have long held a dominant position, while domestic repair products developed by Djn Medical and HanYu Medical have made commercial breakthroughs. The tricuspid valve segment remains a blue ocean. Foreign repair and replacement devices lack sufficient clinical data, whereas HuiHe Medical’s K-Clip, the first approved tricuspid annuloplasty system in China, possesses unique local technical advantages.
Overseas leaders such as Edwards Lifesciences, Abbott, and Medtronic, along with domestic innovators like Venus Medtech, Djn Medical, and HuiHe Medical, have developed distinct competitive strengths through proprietary track-specific technologies, complete product lines, clinical evidence systems, and localized service networks, collectively driving continuous advancement in the global valvular intervention industry.
Looking forward, competition in the aortic and mitral valve markets will become more regular, while the tricuspid valve segment will become the core growth driver of the industry. Original domestic technologies, exemplified by HuiHe Medical, will open up new growth possibilities. The mature operational models of multinational enterprises and the localized innovation approaches of Chinese manufacturers serve as important industry models. By comparing these two approaches, we can promote balanced development in the global structural heart valvular device industry and support its sustainable, long-term expansion.
If you have further research needs regarding China’s cardiovascular interventional device market, please contact us:
Frost & Sullivan Jing Jing
E-mail: jing.jing@frostchina.com
